Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.
How it helps
With In Vivo, you’ll benefit from:
How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.
Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.
In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...
Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.
Topic Coronavirus
In Vivo, Scrip
Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.
In Vivo
The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.
Topic Coronavirus
In Vivo
Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.
Topic BioPharmaceutical
In Vivo
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
In Vivo
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo
Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.
In Vivo
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
In Vivo
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
In Vivo
Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.
In Vivo
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
In Vivo
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”
In Vivo
Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.
In Vivo
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
Topic Business strategies Drug development landscape Research
In Vivo
23 Mar 2020
In Vivo
23 Mar 2020
In Vivo
19 Mar 2020
In Vivo
19 Mar 2020
In Vivo
18 Mar 2020
In Vivo
18 Mar 2020
In Vivo
18 Mar 2020
In Vivo
17 Mar 2020
In Vivo
11 Mar 2020
In Vivo
11 Mar 2020
In Vivo
11 Mar 2020
In Vivo
10 Mar 2020
In Vivo
09 Mar 2020
In Vivo
09 Mar 2020
In Vivo
04 Mar 2020
USA
William specializes in
+40 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
You’ll instantly connect to the latest in global medtech developments with industry news, trends, deals, product developments, opinions, analysis, and context behind the headlines and more – all available at your fingertips.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date